Previous 10 | Next 10 |
Gainers: Kala Pharmaceuticals (NASDAQ:KALA) +20%. Natera (NASDAQ:NTRA) +17%. Chemomab Therapeutics (NASDAQ:CMMB) +13%. Selecta Biosciences (NASDAQ:SELB) +11%. Longeveron (NASDAQ:LGVN) +7%. Losers: Sunshine Biopharma (NASDAQ:SBFM) -32%. My...
Chemomab Therapeutics Ltd (CMMB) Q4 2021 Earnings Conference Call March 9, 2022, 10:00 AM ET Company Participants Dale Pfost – Chief Executive Officer Donald Marvin – Chief Operating Officer and Executive Vice President David Weiner – Chemomab Interim Chief Medical Office...
Chemomab Therapeutics press release (NASDAQ:CMMB): Q4 GAAP EPS of -$0.02 beats by $0.12. Cash, cash equivalents and short-term bank deposits were $61.2 million as of December 31, 2021, compared to $11.8 million as of December 31, 2020. For further details see: Chemomab Therapeutics GAAP...
Chemomab Therapeutics Announces Fourth Quarter and Year End 2021 Financial Results and Provides a Corporate Update --Company Announces Revisions Intended to Optimize CM-101 Clinical Development Program and Produce More Informative Data, More Rapidly and Efficiently; Changes Also...
Chemomab Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Business Update PR Newswire TEL AVIV, Israel , March 2, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd . (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnolo...
Chemomab Therapeutics to Present at Aegis Virtual Conference PR Newswire TEL AVIV, Israel , Feb. 10, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd . (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development o...
The global launch of Bylvay was more successful than expected and Albireo doubled its net sales guidance for 2021. Beyond Odevixibat, Albireo was able to discover new drugs with blockbuster. Both early clinical assets address a market with a high medical need and have blockbuster ...
Chemomab Therapeutics Names Jack Lawler Vice President of Global Clinical Development Operations - Company Also Announces Move to an Expanded Scientific and Business Facility in Israel PR Newswire TEL AVIV, Israel , Jan. 4, 2022 /PRNewswire/ -- Chemomab The...
Chemomab to Participate in LifeSci Partners Annual Corporate Access Event and H.C. Wainwright BioConnect 2022 Healthcare Conference PR Newswire TEL AVIV, Israel , Dec. 20, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stag...
Chemomab Therapeutics Announces Expected Appointment of Dale R. Pfost as Chairman of the Board PR Newswire TEL AVIV, Israel , Dec. 16, 2021 /PRNewswire/ -- Chemomab Therapeutics Ltd . (Nasdaq: CMMB), (Chemomab) a clinical-stage biotechnology company focused o...
News, Short Squeeze, Breakout and More Instantly...
Chemomab Therapeutics Ltd. Company Name:
CMMB Stock Symbol:
NASDAQ Market:
Chemomab Therapeutics Ltd. Website:
—Proteomic Analysis of Patient Samples Further Confirms that CCL24 is Associated with Primary Sclerosing Cholangitis (PSC) Severity and Progression, Highlighting the Potential of Chemomab’s CCL24-Neutralizing Antibody CM-101 as a Promising Therapy for PSC— ...
—Ex Vivo Studies Using Clinical Samples from Patients with Liver Fibrosis Reinforce the Anti-Fibrotic Activity of CM-101 by Showing the Drug’s Direct Interference with Liver Fibroblast Activation— — New Translational Data Further Confirms CM-101’s ...